Defibrotide comment watch save
Breastfeeding

  • TRADE NAME: Defitelio (Jazz)
  • INDICATIONS: Hepatic veno-occlusive disease in patients with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation
  • CLASS: Oligonucleotide
  • HALF-LIFE: <2 hours
  • FDA APPROVAL DATE: 03/30/2016
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    Alteplase, Heparin
  • PREGNANCY: No data available

Contra-indicated for concomitant administration with systemic anticoagulant or fibrinolytic therapy.

Please login to view the rest of this drug profile.

Page last updated 08/20/2025

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top